CN108671383B - Wearable hypertension real-time diagnosis and treatment integrated system capable of controlling drug release - Google Patents
Wearable hypertension real-time diagnosis and treatment integrated system capable of controlling drug release Download PDFInfo
- Publication number
- CN108671383B CN108671383B CN201810554986.5A CN201810554986A CN108671383B CN 108671383 B CN108671383 B CN 108671383B CN 201810554986 A CN201810554986 A CN 201810554986A CN 108671383 B CN108671383 B CN 108671383B
- Authority
- CN
- China
- Prior art keywords
- blood pressure
- microneedle
- hypertension
- drug
- module
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
- A61B5/02133—Measuring pressure in heart or blood vessels by using induced vibration of the blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6802—Sensor mounted on worn items
- A61B5/681—Wristwatch-type devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/30—Blood pressure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
The invention belongs to the technical field of products for diagnosing and treating hypertension, and particularly discloses a wearable hypertension real-time diagnosis and treatment integrated system capable of controlling drug release, which comprises a wearable blood pressure monitoring device and a microneedle type controllable drug delivery device: the wearable blood pressure monitoring device comprises a bracelet worn on a wrist part, wherein a graphene pressure sensor, a signal processing module, a data storage module, a data transmission module and a battery are arranged on the bracelet; the micro-needle type controllable drug delivery device comprises an arm belt worn on an arm part, and a hypertension drug micro-needle, an instruction receiving and controllable releasing module and a micro-needle storage module which are arranged on the arm belt. The system is convenient to use, accurate in diagnosis and treatment, and capable of immediately and accurately administering according to abnormal conditions of blood pressure while monitoring the blood pressure, so that the blood pressure can be regulated and controlled timely and effectively, and the effect of hypertension treatment is effectively improved.
Description
Technical Field
The invention belongs to the technical field of products for diagnosing and treating hypertension, and particularly relates to a wearable real-time diagnosis and treatment integrated system for hypertension with controllable drug release.
Background
In the prior art, along with the gradual acceleration of modern life rhythm and the gradual increase of life pressure of people, the number of people suffering from hypertension presents a remarkable rising trend, and the hypertension is a systemic symptom characterized by the rising of arterial pressure and can be accompanied by the functional or organic change of organs such as heart, blood vessels, brain, kidneys and the like, and diseases such as stroke, myocardial infarction, heart failure, hemangioma, renal failure and the like even cause death when serious are caused, so the hypertension becomes a serious public health problem in the global scope.
Hypertension is a chronic disease, and is difficult to radically cure, and the common clinical treatment mode at present is to use antihypertensive drugs to control the blood pressure within a normal range for a long time, so that hypertension complications are effectively prevented. Diagnosis and treatment of hypertension thus involves long-term blood pressure monitoring and medication.
Currently, clinically applied blood pressure measurement mainly comprises room blood pressure, dynamic blood pressure and home self-measurement blood pressure. The blood pressure of the consulting room and the dynamic blood pressure are needed to be carried out in a hospital, the traditional mercury sphygmomanometer or the automatic sphygmomanometer is needed to be operated by a professional medical staff or large-scale professional equipment is needed, the dynamic sphygmomanometer used by the latter is portable, but has larger volume, a cable is wound on a patient, the measurement is still carried out through cuff pressurization, the comfort level is low, the normal life of the user is greatly influenced, and the continuous use time is usually not longer than 24 hours due to the reasons of electric quantity, sanitation and the like. The home self-testing of the blood pressure is mainly realized through an electronic cuff or a wrist strap sphygmomanometer, the product price is reasonable, the accuracy is high, but the measurement still needs manual active operation, and the measurement frequency is difficult to guarantee in the current fast-paced life. Therefore, these blood pressure detection means cannot meet the requirements of high frequency and even real-time detection of blood pressure in the treatment of hypertension, especially in the treatment of acute hypertension and high-risk patients.
Traditional methods of treating hypertension include oral, sublingual, intravenous, and the like. Wherein, the oral administration is convenient, the skin and the mucous membrane are not damaged, and the price is low. However, oral administration is slow and irregular in absorption because the oral administration firstly enters blood after being digested by intestines and stomach, for example, the antihypertensive drug such as nitroglycerin or sodium nitroprusside usually takes about 15-30 minutes to act, so that the oral administration cannot exert the drug effect in a short time when treating hypertension emergency, and suffocation is easily caused by taking medicine by a person with unconsciousness, so that the gold emergency treatment time of 10 minutes is missed; the sublingual buccal administration is a common treatment method for hypertension, and the medicament directly enters blood through sublingual capillaries to complete the absorption process, so that the first pass effect of liver is avoided, the medicament is completely absorbed and has high speed, but the dosage of sublingual buccal administration is limited; intravenous injection is fast in absorption and can achieve higher dosage, but the intravenous injection can be achieved only in the presence of hospitals or medical professionals, and the possibility of adverse reactions and inconvenience and skin wounds caused by intravenous injection are increased due to the fact that high-concentration medicines rapidly reach plasma and tissues. The treatment of hypertension is a long-term process, the simplest oral administration mode also usually needs to take 1-2 times per day, and acute hypertension and hypertension with multiple complications need to take medicines at higher frequency, so that long-term, on-time and quantitative manual active medicine taking is required, which is also a major problem in the treatment of hypertension, namely that many patients do not take medicines or do not take medicines correctly, so that the treatment effect of regulating blood pressure is poor, blood pressure is repeatedly increased, even serious complications occur, and life is endangered. At present, there is still a lack of more automated modes of administration in the treatment of hypertension, which require less manual intervention.
There are a number of new blood pressure detection and administration modes that are currently in existence. For example, devices for detecting blood pressure at high frequency by using a photoelectric method or a mechanical sensing method are developed, but have a great problem that the detection accuracy is poor, for example, the device can only reflect the trend of the whole blood pressure change, and can not meet the clinical accuracy requirement of plus or minus 5mmHg error with a mercury sphygmomanometer, or the accuracy can be met, but the device is more severe in wearing mode and use condition and is high in price. In the aspect of administration mode, related researches on transdermal administration by using a microneedle device have appeared in recent years, and the painless transdermal administration and the simple and easy use characteristics of the microneedle device are utilized, but the control of the drug dosage is still not accurate enough, and the timely adjustment of the administration amount according to the change of the blood pressure of a patient is difficult, so that the drug dosage is still imperfect. Meanwhile, a diagnosis and treatment system with blood pressure detection and drug administration are not yet developed.
In summary, a hypertension diagnosis and treatment integrated system which is wearable, monitors blood pressure in real time and accurately and immediately feeds medicine when blood pressure is abnormal is developed, and the system has great clinical significance and is urgent.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, and particularly discloses a wearable real-time diagnosis and treatment integrated system for hypertension with controllable drug release.
In order to achieve the technical purpose, the invention is realized according to the following technical scheme:
the invention discloses a wearable type hypertension real-time diagnosis and treatment integrated system capable of controlling drug release, which is characterized by comprising a wearable type blood pressure monitoring device and a microneedle type controllable drug delivery device:
the wearable blood pressure monitoring device comprises a bracelet worn on a wrist part, wherein a graphene pressure sensor, a signal processing module, a data storage module, a data transmission module and a battery are arranged on the bracelet;
wherein: the signal processing module is used for performing digital-to-analog conversion on the electric signal, converting a corresponding radial artery pressure value and a corresponding blood pressure value, judging whether the monitored blood pressure value is normal or not, immediately calculating the corresponding dosage and sending an instruction to the drug delivery device through the data transmission module if the monitored blood pressure value is abnormal, and in addition, the module also has the updating capability of a blood pressure conversion algorithm;
the data storage module is used for storing the blood pressure value in a certain time; providing possibility for data export analysis and assisting in clinical diagnosis of doctors;
the data transmission module is used for exporting monitoring data, sending a drug administration instruction and importing a blood pressure correction algorithm;
the micro-needle type controllable drug delivery device comprises an arm belt worn on the arm part, a hypertension drug micro-needle arranged on the arm belt, an instruction receiving and controllable releasing module and a micro-needle storage module;
wherein: the hypertension drug microneedle comprises a microneedle substrate and a microneedle head;
the instruction receiving module is used for receiving an instruction signal from the wearable blood pressure monitoring device;
the controllable release module is used for reminding the replacement of the micro needle in time;
the microneedle storage module is used for storing the microneedle heads.
As a further improvement of the above technology, the graphene pressure sensor is a wrinkled graphene lamellar structure, and is encapsulated at the wristband part of the wristband, and converts the pressure into an electrical signal by using the stretching-shrinking process of the pressure generated by radial artery pulsation on the graphene structure. The graphene structure realizes accurate detection of a micro pressure signal due to high electron mobility and extremely large specific surface area.
As a further improvement of the above technology, the data transmission module utilizes a bluetooth low energy module or Zigbee to realize the derivation of the monitoring data, the transmission of the drug administration instruction and the import of the blood pressure correction algorithm.
As a further improvement of the above technology, the wearable blood pressure monitoring device further includes a machine learning server, specifically: the blood pressure value acquired and converted by the bracelet is compared, analyzed and learned through the machine learning server and the blood pressure measured by the dynamic sphygmomanometer in the first 24 hours of initial use, an effective correction algorithm specific to a specific user is obtained, in the subsequent use, 24 hours of correction is carried out every 1 month, the correction algorithm is updated, and the blood pressure is imported into the bracelet signal processing module, so that high-accuracy blood pressure measurement is obtained.
In the present invention, the microneedle substrate is composed of Polydimethylsiloxane (PDMS) or photo-crosslinked polyethylene glycol monomethyl ether-methacrylate (PEG) or photo-crosslinked trimethylolpropane triacrylate (TMPTA) which are biocompatible but insoluble in water.
In the present invention, the microneedle has a length of not more than 800 μm.
In the invention, the outside of the micro-needle is made of hydroxymethyl cellulose (CMC) or polyvinylpyrrolidone (PVP) or sodium alginate or hyaluronic acid material, photosensitive liposome nanoparticle balls are uniformly distributed in the micro-needle, the photosensitive liposome nanoparticle balls comprise liposome nanoparticles, gold nanorods and antihypertensive drugs, and the antihypertensive drugs are wrapped in the liposome nanoparticles and the gold nanorods.
In the invention, the liposome particles have a phospholipid bilayer structure.
In the invention, the controllable release module starts a light-emitting diode (LED) light source according to the time and the intensity required by instructions, the wavelength of the light source is between green light and near infrared wave band (the wavelength is 500-1000 nm), the transdermal part of the micro needle point is irradiated, the content of the subcutaneous residual medicine is calculated according to the time and the intensity of illumination, and when the content of the medicine which is not released under the skin is lower than 20% of the total content of the medicine of a single micro needle, a user is reminded of replacing the micro needle in a vibration mode.
In the invention, the microneedle storage modules are of a rotary drum design, a piece of hypertension drug microneedles is stored in each rotary drum, and the microneedle storage modules are connected with a counter on the controllable release module and used for triggering the counter on the controllable release module to update the numerical value of the content of the residual drugs in the controllable release module.
Compared with the prior art, the invention has the beneficial effects that:
(1) The hypertension real-time diagnosis and treatment integrated system fully utilizes the high sensitivity of the graphene sensor to detect the pressure generated by weak pulse, combines machine learning and timely corrects a conversion algorithm of a blood pressure value, and realizes real-time accurate blood pressure monitoring;
(2) The hypertension real-time diagnosis and treatment integrated system fully utilizes photosensitive liposome nano particles to realize the controllable release of antihypertensive drug molecules;
(3) The hypertension real-time diagnosis and treatment integrated system organically combines the blood pressure monitoring device and the microneedle type drug release device to form a diagnosis and treatment system by using a wireless transmission technology, immediately calculates the required drug quantity when the abnormal blood pressure is detected, and accurately releases the corresponding drug quantity by controlling the time and the intensity of illumination so as to realize the real-time accurate regulation and control of the blood pressure.
Drawings
The invention is described in detail below with reference to the attached drawings and specific examples:
fig. 1 is a schematic structural diagram of a wearable real-time diagnosis and treatment integrated system for hypertension.
Fig. 2 is a schematic structural view of the blood pressure monitor.
FIG. 3 is a schematic structural view of a microneedle type controllable drug delivery device;
FIG. 4 is a schematic structural view of a hypertension drug microneedle according to the present invention;
FIG. 5 is a schematic view of the microneedle and its internal structure according to the present invention;
fig. 6 is a schematic flow chart of the release of antihypertensive drug by the microneedle.
In the figure:
wherein the numerical designation refers to the name:
1-blood pressure monitoring device
10-pressure sensor flexible housing
11-graphene pressure sensor
12-data storage module
13-Signal processing Module
14-data transmission module
15-lithium battery
2-microneedle type controllable drug delivery device
21-hypertension medicine microneedle
211-microneedle substrate
212-microneedle head
213-photosensitive Liposome nanoparticle spheres
2131-liposome nanoparticles
2132-gold nanorods
2133-antihypertensive medicine
22-spent hypertensive drug microneedle
23-instruction receiving module
24-controlled release module
25-microneedle storage module
3-machine learning server
Detailed Description
As shown in fig. 1, the wearable type controllable drug release hypertension real-time diagnosis and treatment integrated system provided by the invention comprises a wearable blood pressure monitoring device 1 and a microneedle type controllable drug delivery device 2, and further comprises a machine learning server 3.
As shown in fig. 2, the wearable blood pressure monitoring device 1 includes a wristband worn on a wrist, and a pressure sensor flexible housing 10, a graphene pressure sensor 11, a signal processing module 13, a data storage module 12, a data transmission module 14, and a lithium battery 15 are disposed on the wristband.
The graphene pressure sensor 11 is located inside a watchband, specifically, a wrinkled graphene lamellar structure is packaged at the wristband part of the wristband, weak pulse pressure signals are converted into electric signals by utilizing the stretching-shrinking process of pressure generated by radial artery pulsation on the graphene structure, and the graphene structure realizes accurate detection of micro pressure signals due to high electron mobility and extremely large specific surface area.
The signal processing module 13 converts the electrical signals collected by the graphene pressure sensor 11 into blood pressure values, calculates the required medicine amount when the blood pressure is abnormal, and sends related instructions.
The data storage module 12 is configured to store blood pressure monitoring data within a certain period of time, and the data transmission module 14 plays a role of communicating with the outside through bluetooth low energy or Zigbee, and includes guiding the microneedle type controllable drug delivery device 2 of the signal processing module 13, guiding the blood pressure data stored in the data storage module 12 to the server 3 for machine learning, and transmitting the corrected blood pressure conversion algorithm back to the signal processing module 13.
As shown in fig. 3, the microneedle type controllable drug delivery device 2 comprises an arm belt worn on an arm part, and a hypertension drug microneedle 21, a command receiving module 23, a controllable release module 24 and a microneedle storage module 25 which are arranged on the arm belt 20.
As shown in fig. 4, the hypertension drug microneedle 21 includes a microneedle base 211 and a microneedle head 212; the microneedle substrate 211 is composed of Polydimethylsiloxane (PDMS) or photo-cured polyethylene glycol monomethyl ether-methacrylate (PEG) or photo-crosslinked trimethylolpropane triacrylate (TMPTA) that is biocompatible but insoluble in water.
The microneedle 212 has a length of not more than 800 μm, and the microneedle 212 is inserted into the skin surface but is not enough to stimulate subcutaneous nerves, so that pain is not caused, and has a suitable length.
In the present invention, the outer portion of the microneedle 212 is made of hydroxymethyl cellulose (CMC) or polyvinylpyrrolidone (PVP) or sodium alginate or hyaluronic acid material, and the inner portion of the microneedle 212 is uniformly distributed with photosensitive liposome nanoparticle spheres 213, as shown in fig. 5. The photosensitive liposome nanoparticle spheres 213 include liposome nanoparticles 2131, gold nanorods 2132 and a antihypertensive drug 2133, the antihypertensive drug 2133 is encapsulated inside the liposome nanoparticles 2131 and gold nanorods 2132, and the antihypertensive drug 2133 includes, but is not limited to, beta-receptor blockers, calcium channel antagonists, RAS system blockers, alpha 1 -a receptor blocker, a diuretic, one or any two or more drugs of nitroglycerin, sodium nifurate.
In the present invention, the manufacturing process of the photosensitive liposome nanoparticle spheres 213 and the microneedle 212 is as follows:
(1) First, drug molecules 2133 are encapsulated in liposome nanoparticle 2131 doped with gold nanorods 2132 to prepare photosensitive liposome nanoparticle spheres 213;
(2) Then, the photosensitive liposome nanoparticle spheres 213 are added to the outer material layer of the microneedle 212, and the microneedle 212 having the liposome nanoparticle 213 uniformly distributed inside is finally obtained.
In the invention, the liposome nano particles 2131 have a phospholipid bilayer structure, can protect medicine molecules of the internal antihypertensive medicine 2133 from being dissolved in tissue fluid and being stable under the skin within a certain time, when being irradiated by green light-near infrared band light (wavelength is 500-1000 nm) from a controllable release module, the gold nano rods doped in the liposome absorb light energy and convert the light energy into heat energy, the liposome particles are broken to release the medicine, the controllable release of the antihypertensive medicine is realized by controlling the time and the intensity of the light irradiation, the dosage of the medicine contained in one microneedle is preferably about 48 hours, and the captopril is taken as an example, about 50mg of captopril is needed for 60kg of patients each day, and the captopril content in each microneedle is 100mg.
In the present invention, the controllable release module 24 may activate a Light Emitting Diode (LED) light source according to the time and intensity required by the instruction, the wavelength of the light source is between the green light and the near infrared band (wavelength is 500-1000 nm), the transdermal site of the microneedle is irradiated, the content of the remaining drug under the skin is calculated according to the time and intensity of the illumination, and when the content of the drug which is not released under the skin is lower than 20% of the total content of the drug of the single microneedle, the user is reminded to replace the microneedle in a vibration mode.
In the present invention, the microneedle storage module 25 is configured as a drum, each drum stores a piece of hypertensive drug microneedle, and the microneedle storage module 25 is connected with a counter on the controllable release module 24 to trigger the counter on the controllable release module, so as to update the value of the content of the remaining drug in the controllable release module.
When in use, the utility model is characterized in that:
first, each drum of the microneedle storage module 25 is filled with one microneedle;
then, as shown in fig. 6, the hypertensive drug microneedle 21 located below the controlled release module 24 is pressed into the skin (the controlled release module 24 can be rotated aside when pressed into the microneedle), at which time the microneedle 212 is dissolved subcutaneously, releasing the liposome nanoparticle 213 inside. When the command receiving module 23 receives the administration signal from the blood pressure monitoring device 1, the controllable releasing module 24 starts the LED light source to irradiate the skin according to the time and the intensity required by the command, heats the gold nanorods 2132 on the liposome particles 213, breaks the phospholipid bilayer structure of the liposome nanoparticles 2131, enables the antihypertensive drug molecules 2133 with corresponding doses to be released into tissue fluid, and regulates the blood pressure to a normal level; when the content of unreleased drug is lower than 20% of the total drug content of the single microneedle, the instruction receiving module 23 sends out vibration prompt, and the user rotates the microneedle storage module 25 by one lattice, presses a new microneedle, and takes out the used microneedle 22 with dissolved microneedle.
The diagnosis and treatment integrated system further comprises a machine learning server 3, specifically: the blood pressure value acquired and converted by the bracelet is compared, analyzed and learned through the machine learning server 3 and the blood pressure measured by the dynamic blood pressure meter in the first 24 hours of initial use, an effective correction algorithm personalized for a specific user is obtained, in the subsequent use, 24 hours of correction is carried out every 1 month, the correction algorithm is updated, and the blood pressure is imported into the bracelet signal processing module, so that high-accuracy blood pressure measurement is obtained.
The following is described by the level of regulation of two specific examples:
example 1:
hypertension patient a, male, age 40, had a room blood pressure measurement of 150mmHg systolic, 95mmHg diastolic, and was diagnosed as mild (grade 1) hypertension. The antihypertensive drug is captopril, the transdermal administration dosage is 50 mg/day, and the single-chip microneedle contains 100mg of captopril and meets the requirement of 48-hour continuous blood pressure regulation. The blood pressure monitoring device collects blood pressure values every 1min, sets systolic pressure 135mmHg and diastolic pressure 90mmHg as threshold values, sends instructions to the drug administration device to release 5mg of drug when the blood pressure exceeds any value, and collects blood pressure values every 30s within 5 min. After 5 minutes, if the systolic pressure drop is more than or equal to 5mmHg and the diastolic pressure drop is more than or equal to 3mmHg, judging that the blood pressure regulation is effective, and not continuing to administer the medicine; if any condition is not met, 5mg of medicine is released again until the blood pressure regulation and control effective judgment rule is met.
Example 2:
hypertension patient B, female, 50 years old, had room blood pressure measured at systolic pressure 170mmHg, diastolic pressure 105mmHg, and was diagnosed as moderate (grade 2) hypertension. The antihypertensive drugs are captopril and nifedipine, and the transdermal administration doses are 100 mg/day and 30 mg/day respectively. The monolithic microneedle contained 200mg captopril and 60mg nifedipine. The blood pressure monitoring device collects blood pressure values every 30s, sets systolic pressure 135mmHg and diastolic pressure 90mmHg as threshold values, sends instructions to the drug administration device to release 10mg of captopril and 3mg of nifedipine when the blood pressure exceeds any one of the values, and collects the blood pressure values every 20s within 3 minutes. After 3 minutes, if the systolic pressure drop is more than or equal to 5mmHg and the diastolic pressure drop is more than or equal to 3mmHg, judging that the blood pressure regulation is effective, releasing 10mg of captopril and 3mg of nifedipine again, and circulating until the systolic pressure is lower than 130mmHg and the diastolic pressure is lower than 90mmHg; if the above drop value is not met after 3 minutes, the dosage is judged to be increased, then 20mg of captopril and 6mg of nifedipine are released, the above steps are circulated until the effective judgment of blood pressure regulation is met, the release dosage is reduced to 10mg of captopril and 3mg of nifedipine, and then the blood pressure is continuously monitored and corresponding medicine release is carried out until the systolic pressure is lower than 130mmHg and the diastolic pressure is lower than 90mmHg.
The present invention is not limited to the above-described embodiments, and various modifications or variations of the present invention are intended to be included in the present invention, provided that they fall within the scope of the appended claims and the equivalents thereof, unless they depart from the spirit and scope of the present invention.
Claims (6)
1. The wearable hypertension real-time diagnosis and treatment integrated system capable of controlling drug release is characterized by comprising a wearable blood pressure monitoring device, a microneedle type controllable drug delivery device and a machine learning server;
the wearable blood pressure monitoring device comprises a bracelet worn on a wrist part, wherein a graphene pressure sensor, a signal processing module, a data storage module, a data transmission module and a battery are arranged on the bracelet; the micro-needle type controllable drug delivery device comprises an arm belt worn on the arm part, a hypertension drug micro-needle arranged on the arm belt, an instruction receiving and controllable releasing module and a micro-needle storage module; wherein: the hypertension drug microneedle comprises a microneedle substrate and a microneedle head;
the outside of the microneedle is made of hydroxymethyl cellulose or polyvinylpyrrolidone or sodium alginate or hyaluronic acid, photosensitive liposome nanoparticle balls are uniformly distributed in the microneedle, each photosensitive liposome nanoparticle ball comprises a liposome nanoparticle, a gold nanorod and a antihypertensive drug, the antihypertensive drug is wrapped in the liposome nanoparticle and the gold nanorod, the hypertension drug microneedle is pressed into the skin, and the microneedle is dissolved under the skin to release the liposome nanoparticle balls in the interior;
wherein: the signal processing module is used for performing digital-to-analog conversion on the electric signal, converting a corresponding radial artery pressure value and a corresponding blood pressure value, judging whether the monitored blood pressure value is normal or not, calculating the required medicine amount when the blood pressure is abnormal, and sending a related medicine administration instruction;
the data storage module is used for storing the blood pressure value in a certain time;
the data transmission module is used for guiding out the blood pressure data stored by the data storage module to the machine learning server, sending the drug administration instruction to the microneedle type controllable drug administration device and guiding in the blood pressure correction algorithm, and transmitting the blood pressure correction algorithm back to the signal processing module;
the method comprises the steps that in the first 24 hours of initial use, the blood pressure value acquired and converted by a bracelet is compared, analyzed and learned through a machine learning server and the blood pressure measured by a dynamic blood pressure meter, an effective personalized correction algorithm for a specific user is obtained, in the later use, 24 hours of correction is carried out every 1 month, the correction algorithm is updated, and the blood pressure is imported into a bracelet signal processing module, so that high-accuracy blood pressure measurement is obtained;
the instruction receiving module is used for receiving an administration instruction signal from the wearable blood pressure monitoring device;
the controllable release module starts a light source of a light diode according to the time and the intensity required by instructions, the wavelength of the light source is between green light and near infrared wave bands, the wavelength is 500-1000nm, the transdermal part of the micro-needle tip is irradiated, the light energy absorbed by the gold nanorods doped in the liposome is converted into heat energy, and liposome particles are broken, so that the medicine is released;
calculating the content of the subcutaneous residual medicine according to the illumination time and intensity, and when the content of the medicine which is not released subcutaneously is lower than 20% of the total content of the medicines of the single micro-needle, sending out a vibration prompt by the instruction receiving module, enabling a user to rotate the micro-needle storage module for one cell, pressing a new micro-needle into the micro-needle storage module, and taking out the micro-needle which is dissolved by the micro-needle after use;
the microneedle storage module is used for storing microneedle heads, is of a rotary drum design, and each rotary drum is internally provided with a piece of hypertensive drug microneedle, and is connected with a counter on the controllable release module and used for triggering the counter on the controllable release module to update the numerical value of the content of the residual drug in the controllable release module.
2. The wearable real-time diagnosis and treatment integrated system for hypertension with controllable drug release according to claim 1, wherein the graphene pressure sensor is a wrinkled graphene lamellar structure packaged on a wristband part of a bracelet, and converts pressure into an electric signal by utilizing a stretching-shrinking process of pressure generated by radial artery pulsation on the graphene structure, so that the graphene structure realizes accurate detection of a micro pressure signal due to high electron mobility and extremely large specific surface area.
3. The wearable real-time diagnosis and treatment integrated system for hypertension with controllable drug release according to claim 2, wherein the data transmission module utilizes a bluetooth low energy module or Zigbee to realize the export of monitoring data, the sending of drug administration instructions and the import of a blood pressure correction algorithm.
4. The wearable and controllable drug release integrated hypertension real-time diagnosis and treatment system according to claim 1, wherein the microneedle substrate is composed of biocompatible but water-insoluble polydimethylsiloxane or photo-crosslinked polyethylene glycol monomethyl ether-methacrylate or photo-crosslinked trimethylolpropane triacrylate.
5. The wearable, controllable, drug-releasing, integrated system for real-time diagnosis and treatment of hypertension according to claim 1, wherein the length of the microneedle is not more than 800 μm.
6. The wearable real-time diagnosis and treatment integrated system for hypertension with controllable drug release according to claim 1, wherein the liposome particles have a phospholipid bilayer structure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810554986.5A CN108671383B (en) | 2018-06-01 | 2018-06-01 | Wearable hypertension real-time diagnosis and treatment integrated system capable of controlling drug release |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810554986.5A CN108671383B (en) | 2018-06-01 | 2018-06-01 | Wearable hypertension real-time diagnosis and treatment integrated system capable of controlling drug release |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108671383A CN108671383A (en) | 2018-10-19 |
| CN108671383B true CN108671383B (en) | 2023-08-11 |
Family
ID=63809434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810554986.5A Active CN108671383B (en) | 2018-06-01 | 2018-06-01 | Wearable hypertension real-time diagnosis and treatment integrated system capable of controlling drug release |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108671383B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110051340A (en) * | 2019-05-31 | 2019-07-26 | 南京医科大学 | A kind of dynamic dropping equipment of real-time monitoring blood pressure |
| CN110353867A (en) * | 2019-08-06 | 2019-10-22 | 谢恩泽华 | A kind of intelligence initiative pulse support blood vessel and its control method |
| CN110584633A (en) * | 2019-09-06 | 2019-12-20 | 湘南学院附属医院 | Hypertension real-time diagnosis and treatment integrated system capable of controlling drug release |
| CN112827061A (en) * | 2021-02-26 | 2021-05-25 | 中山大学 | Drug release control device, control method thereof, and computer-readable storage medium |
| CN112870543B (en) * | 2021-02-26 | 2022-06-21 | 中山大学 | Drug release control device, control method thereof, and computer-readable storage medium |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200824737A (en) * | 2006-12-06 | 2008-06-16 | Tzung-Hang Lee | Implanted, automatic, periodically and quantitatively medicine-release biochip |
| CN103284951A (en) * | 2013-04-27 | 2013-09-11 | 浙江大学 | Photosensitive liposome with encapsulated water-soluble medicament |
| CN104645331A (en) * | 2015-01-26 | 2015-05-27 | 西安交通大学 | Drug-loading micro-needle promoted and controlled by nanogold photo-thermal effect |
| CN104688210A (en) * | 2015-02-28 | 2015-06-10 | 崔建忠 | Robot medicine delivery system capable of automatically monitoring, analyzing and adjusting blood pressure |
| WO2016023153A1 (en) * | 2014-08-11 | 2016-02-18 | 罗伯特⋅葛伦 | Intelligent medicine-reminder medicine box, medicine-reminder apparatus and medicine-reminder method |
| CN205787635U (en) * | 2016-07-06 | 2016-12-07 | 成都视必康医疗科技有限公司 | A kind of Graphene sphygomanometer wrist-watch |
| CN106943134A (en) * | 2017-03-15 | 2017-07-14 | 陶军 | A kind of wearable blood pressure regulation device |
| WO2017193615A1 (en) * | 2016-05-07 | 2017-11-16 | 深圳市前海康启源科技有限公司 | Medication administration reminder system and method for high blood pressure patient |
| CN107397542A (en) * | 2017-09-15 | 2017-11-28 | 中国科学院重庆绿色智能技术研究院 | A kind of ambulatory blood pressure monitoring Wearable and monitoring method based on pulse wave sensor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070276211A1 (en) * | 2006-05-26 | 2007-11-29 | Jose Mir | Compact minimally invasive biomedical monitor |
| US8702614B2 (en) * | 2011-11-08 | 2014-04-22 | Elwha Llc | Inflatable cuff with built-in drug delivery device for dynamic drug therapy response to blood pressure incidents |
| US20160310593A1 (en) * | 2013-12-11 | 2016-10-27 | Okinawa Institute Of Science And Technology School Corporation | Method for controlled release with femtosecond laser pulses |
| US10716518B2 (en) * | 2016-11-01 | 2020-07-21 | Microsoft Technology Licensing, Llc | Blood pressure estimation by wearable computing device |
-
2018
- 2018-06-01 CN CN201810554986.5A patent/CN108671383B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200824737A (en) * | 2006-12-06 | 2008-06-16 | Tzung-Hang Lee | Implanted, automatic, periodically and quantitatively medicine-release biochip |
| CN103284951A (en) * | 2013-04-27 | 2013-09-11 | 浙江大学 | Photosensitive liposome with encapsulated water-soluble medicament |
| WO2016023153A1 (en) * | 2014-08-11 | 2016-02-18 | 罗伯特⋅葛伦 | Intelligent medicine-reminder medicine box, medicine-reminder apparatus and medicine-reminder method |
| CN104645331A (en) * | 2015-01-26 | 2015-05-27 | 西安交通大学 | Drug-loading micro-needle promoted and controlled by nanogold photo-thermal effect |
| CN104688210A (en) * | 2015-02-28 | 2015-06-10 | 崔建忠 | Robot medicine delivery system capable of automatically monitoring, analyzing and adjusting blood pressure |
| WO2017193615A1 (en) * | 2016-05-07 | 2017-11-16 | 深圳市前海康启源科技有限公司 | Medication administration reminder system and method for high blood pressure patient |
| CN205787635U (en) * | 2016-07-06 | 2016-12-07 | 成都视必康医疗科技有限公司 | A kind of Graphene sphygomanometer wrist-watch |
| CN106943134A (en) * | 2017-03-15 | 2017-07-14 | 陶军 | A kind of wearable blood pressure regulation device |
| CN107397542A (en) * | 2017-09-15 | 2017-11-28 | 中国科学院重庆绿色智能技术研究院 | A kind of ambulatory blood pressure monitoring Wearable and monitoring method based on pulse wave sensor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108671383A (en) | 2018-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108671383B (en) | Wearable hypertension real-time diagnosis and treatment integrated system capable of controlling drug release | |
| US9028407B1 (en) | Methods and apparatus for monitoring patient conditions | |
| AU2010302270B2 (en) | Continuous non-interfering health monitoring and alert system | |
| WO2008116822A3 (en) | Device for the medical care of a patient in an emergency | |
| Khandpur | Compendium of Biomedical Instrumentation, 3 Volume Set | |
| CN106943134A (en) | A kind of wearable blood pressure regulation device | |
| CN203314955U (en) | Cardiogram monitor special for pediatric nursing | |
| CN117043883A (en) | Thoracic postoperative monitoring and complications prediction | |
| US20210060317A1 (en) | Opioid overdose rescue device | |
| Chinnadurai et al. | Comparison of an implantable telemetry device and an oscillometric monitor for measurement of blood pressure in anaesthetized and unrestrained green iguanas (Iguana iguana) | |
| CN110584633A (en) | Hypertension real-time diagnosis and treatment integrated system capable of controlling drug release | |
| CN110946721B (en) | Department of neurology sleep monitoring first aid device | |
| Gray et al. | Effects of sex and cuff pressure on physiological responses during blood flow restriction resistance exercise in young adults | |
| CN106419848A (en) | Device and method for monitoring thyroid function | |
| CN112870543B (en) | Drug release control device, control method thereof, and computer-readable storage medium | |
| TW200922520A (en) | System and method for wireless physiological signal integration | |
| CN113520804B (en) | A recovered and complication monitoring devices that is used for hip fracture postoperative | |
| WO2022192762A1 (en) | Ingestible anxiety monitoring and treatment system | |
| CN202426744U (en) | Hypoglycemia first aid box | |
| Mattson et al. | The effect of hypovolemia due to hemorrhage on the minimum alveolar concentration of isoflurane in the dog | |
| CN117043882A (en) | Preoperative and intraoperative data for suggesting postoperative monitoring and sensing protocols | |
| CN208144992U (en) | A kind of portable simple gastroscope biting | |
| CN209611238U (en) | Radial artery compressor with automatic bleeding alarm function | |
| CN220141643U (en) | Nursing of intracardiac branch of academic or vocational study is with guardianship braces | |
| WO2023133510A1 (en) | Methods for reducing the risk of strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20221215 Address after: 510080 No. two, No. 58, Zhongshan Road, Guangdong, Guangzhou Applicant after: THE FIRST AFFILIATED HOSPITAL OF SUN YAT-SEN University Address before: 510080 No. two, No. 58, Zhongshan Road, Guangdong, Guangzhou Applicant before: Tao Jun |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |